Organogenesis Holdings Inc. (ORGO) stock
ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.81+0.01 (+1.06%)
Close on Nov 17, 2026Market cap $104.43MP/E –Yield –
Organogenesis r&d expenses
Research and development expenses are spending on new products and technology.
Organogenesis's R&D Expenses for the twelve months ending Jun 30, 2026 was $56.97M, up 32.8% year over year. For fiscal 2025 it was $44.54M, down 11.4% from the year before. The highest annual figure on record is $50.27M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.54M | -11.4% |
| FY2024 | Dec 31, 2024 | $50.27M | +13.3% |
| FY2023 | Dec 31, 2023 | $44.38M | +11.6% |
| FY2022 | Dec 31, 2022 | $39.76M | +29.3% |
| FY2021 | Dec 31, 2021 | $30.74M | +53.1% |
| FY2020 | Dec 31, 2020 | $20.09M | +35.7% |
| FY2019 | Dec 31, 2019 | $14.80M | +37.8% |
| FY2018 | Dec 31, 2018 | $10.74M | +18.5% |
| FY2017 | Dec 31, 2017 | $9.07M | +44.4% |
| FY2016 | Dec 31, 2016 | $6.28M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $18.30M | +76.0% |
| Q1 FY2026 | Mar 31, 2026 | $15.16M | +42.5% |
| Q4 FY2025 | Dec 31, 2025 | $10.29M | -10.8% |
| Q3 FY2025 | Sep 30, 2025 | $13.22M | +27.8% |
| Q2 FY2025 | Jun 30, 2025 | $10.40M | -33.3% |
| Q1 FY2025 | Mar 31, 2025 | $10.64M | -16.9% |
| Q4 FY2024 | Dec 31, 2024 | $11.53M | -2.0% |
| Q3 FY2024 | Sep 30, 2024 | $10.34M | -1.2% |
| Q2 FY2024 | Jun 30, 2024 | $15.59M | +42.5% |
| Q1 FY2024 | Mar 31, 2024 | $12.81M | +14.4% |
| Q4 FY2023 | Dec 31, 2023 | $11.77M | +3.3% |
| Q3 FY2023 | Sep 30, 2023 | $10.47M | +9.3% |
| Q2 FY2023 | Jun 30, 2023 | $10.94M | +7.2% |
| Q1 FY2023 | Mar 31, 2023 | $11.20M | +30.5% |
| Q4 FY2022 | Dec 31, 2022 | $11.40M | +38.0% |
| Q3 FY2022 | Sep 30, 2022 | $9.58M | +6.9% |
| Q2 FY2022 | Jun 30, 2022 | $10.21M | +39.4% |
| Q1 FY2022 | Mar 31, 2022 | $8.59M | +38.3% |
| Q4 FY2021 | Dec 31, 2021 | $8.26M | +31.1% |
| Q3 FY2021 | Sep 30, 2021 | $8.95M | +141.4% |
| Q2 FY2021 | Jun 30, 2021 | $7.32M | +56.8% |
| Q1 FY2021 | Mar 31, 2021 | $6.21M | +14.8% |
| Q4 FY2020 | Dec 31, 2020 | $6.30M | +73.0% |
| Q3 FY2020 | Sep 30, 2020 | $3.71M | -5.5% |
| Q2 FY2020 | Jun 30, 2020 | $4.67M | +20.8% |
| Q1 FY2020 | Mar 31, 2020 | $5.41M | +60.5% |
| Q4 FY2019 | Dec 31, 2019 | $3.64M | +17.8% |
| Q3 FY2019 | Sep 30, 2019 | $3.92M | +41.2% |
| Q2 FY2019 | Jun 30, 2019 | $3.86M | +88.7% |
| Q1 FY2019 | Mar 31, 2019 | $3.37M | +19.4% |
| Q4 FY2018 | Dec 31, 2018 | $3.09M | +13.0% |
| Q3 FY2018 | Sep 30, 2018 | $2.78M | +19.5% |
| Q2 FY2018 | Jun 30, 2018 | $2.05M | -16.5% |
| Q1 FY2018 | Mar 31, 2018 | $2.82M | +82.1% |
| Q4 FY2017 | Dec 31, 2017 | $2.74M | – |
| Q3 FY2017 | Sep 30, 2017 | $2.33M | – |
| Q2 FY2017 | Jun 30, 2017 | $2.45M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.55M | – |
See a number that looks wrong?